B. Riley analyst Kalpit Patel raised the firm’s price target on Mirati Therapeutics to $56 from $52 and keeps a Neutral rating on the shares after the FDA cleared the Investigational New Drug application for MRTX1133. The analyst acknowledges the potential for robust Phase I data for MRTX1133 serves as a key risk to the firm’s neutral thesis. However, it is unclear whether the drug can achieve plasma exposures required for such clinical activity, B. Riley tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics says FDA clears IND application of MRTX1133
- Short Report: Bearish views reach record high on Silvergate, Mirati Therapeutics
- Mirati Therapeutics gets FDA breakthrough therapy designation for adagrasib
- Sell these stocks now, proven algorithm says
- Mirati Therapeutics initiated with a Hold at Needham
